Background Open-label platform trials and a prospective meta-analysis suggest efficacy of
anti–interleukin (IL)-6R therapies in hospitalized patients with coronavirus disease 2019 …

ABSTRACT BACKGROUND Sarilumab (anti-interleukin-6 receptor-α monoclonal antibody)
may attenuate the inflammatory response in Covid-19. METHODS We performed an …

Background Elevated proinflammatory cytokines are associated with greater COVID-19
severity. We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor …

Introduction SARS-CoV-2 pneumonia is often associated with hyper-inflammation. The
cytokine-storm-like is one of the targets of current therapies for coronavirus disease 2019 …

The objective of this study was to investigate the efficacy and safety of early treatment with
sarilumab, added to standard of care (SOC), in hospitalized adults with COVID-19. Methods …

Background Interleukin-6 signal blockade showed preliminary beneficial effects in treating
inflammatory response against SARS-CoV-2 leading to severe respiratory distress. Herein …

Background Patients with COVID-19 pneumonia can have increased inflammation and
elevated cytokines, including interleukin (IL)-6, which might be deleterious. Thus, sarilumab …

Importance and objective The aim of this pragmatic, embedded, adaptive trial was to
measure the effectiveness of the subcutaneous anti-IL-6R antibody sarilumab, when added …

Background. It has been found that there is overactivation of immune response in patients
with COVID‐19. Several studies are going on to assess the role of immunomodulation. IL‐6 …

Objectives In some patients, acute, life-threatening respiratory injury produced by viruses
such as SARS-CoV and other viral pneumonia are associated with an over-exuberant …